Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
The Pharma Data
NOVEMBER 10, 2020
“They will help researchers mechanistically assess target engagement in clinical trials,” and also will be used in clinical practice to identify the right drugs for the right patients, Howard Fillet, M.D., We wanted a tau antibody that would bind to the expressed forms of tau, so we developed a very specific assay,” Dage said.
52 
Let's personalize your content